Prelude Therapeutics Inc. — Q3 2020 Form 10-Q
Reporting period: Three and nine months ended September 30, 2020. The company is a clinical-stage precision oncology developer with no product revenue. Amounts below are in U.S. dollars; financial figures are in millions unless stated otherwise.
Business context and pipeline
Prelude is developing small-molecule cancer therapies. Its three clinical-stage candidates are PRT543 and PRT811, both PRMT5 inhibitors, and PRT1419, an MCL1 inhibitor. The company reported three additional programs in preclinical development and planned to begin advancing programs into clinical development in 2021.
Financial performance and position
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $15.3 | $5.5 | $33.6 | $15.4 |
| General and administrative expense | $2.9 | $1.4 | $5.7 | $2.6 |
| Total operating expenses | $18.1 | $6.9 | $39.3 | $18.0 |
| Other income, net | $1.4 | $0.2 | $1.6 | $0.5 |
| Net loss | $(16.8) | $(6.7) | $(37.7) | $(17.5) |
| Basic and diluted net loss per share | $(5.25) | $(3.93) | $(15.83) | $(10.80) |
- At September 30, cash and cash equivalents were $234.8, total assets $239.7, total liabilities $11.4, and stockholders’ equity $228.3. Accumulated deficit was $88.2.
- Current assets of $238.1 less current liabilities of $11.4 imply working capital of approximately $226.7. The balance sheet reported no capital lease obligation at quarter-end; the filing reports no credit facility or committed capital sources.
- For the first nine months, operating cash use was $31.3, investing cash use $0.3, and financing cash provided $247.5. Cash increased by $215.9 from $18.9 at year-end 2019.
- No meaningful operating margin is reported; the company had no revenue and incurred operating losses.
Changes versus the comparable period
- Q3 R&D expense rose $9.8 year over year; nine-month R&D rose $18.2. Management attributed the increases primarily to clinical research, enrollment and monitoring for PRT543 and PRT811, initiation of the PRT1419 trial, and related chemistry and manufacturing costs.
- Q3 G&A expense increased $1.5 year over year and nine-month G&A increased $3.1, reflecting headcount, professional fees, expanded operations, and public-company costs.
- Net loss widened by $10.0 in Q3 and $20.1 for the nine-month period. Other income increased, primarily because of a Delaware research and development tax credit recognized in Q3.
- September’s IPO raised approximately $166.6 net proceeds as disclosed in the notes. The company also received approximately $49.8 net from Series C preferred shares and $29.9 net from Series B shares during 2020. Preferred shares converted into common stock upon the IPO. The IPO and the retrospective adjustment for a 1.1566-for-one reverse split affect comparison of per-share figures.
Outlook, commentary, risks and unusual items
- Management expected existing cash to fund operating expenses and capital expenditures into the second half of 2022, while cautioning that estimates depend on assumptions and capital could be used sooner. Additional funding may be needed thereafter; no financing was committed.
- Management expected R&D spending to increase significantly as trials and programs advance, and G&A to rise with growth and public-company obligations. No product revenue was expected in the foreseeable future.
- Clinical outlook: planned PRT543 solid-tumor expansion enrollment in Q4 2020 and myeloid-malignancy cohorts in early 2021, with initial expansion data anticipated in the first half of 2021. PRT811 dose expansion enrollment was expected in the first half of 2021, with initial data anticipated by year-end 2021. These are management expectations, not guarantees.
- Management reported early clinical activity: a confirmed complete response in one HRD-positive ovarian cancer patient in the PRT543 Phase 1 trial, and a partial response by RANO criteria at week 16 for a refractory glioblastoma patient receiving PRT811. The filing emphasizes that the trials are early-stage, involve limited patient numbers, and these observations do not establish efficacy or predict later results.
- PRT1419’s Phase 1 trial had recently begun. Management said the lead programs and research activities remained on track amid COVID-19, but the filing disclosed limited delays in some trial-site initiations, patient participation and enrollment. Further trial, vendor, enrollment, cost and timeline impacts remained uncertain.
- Reported PRT543 safety observations included reversible Grade 4 thrombocytopenia at the highest dose; other listed events were not considered related to treatment. PRT811 events included nausea, constipation, vomiting and hyponatremia, none considered related in the filing. Safety and efficacy remain uncertain.
- Subsequent event: on November 1, 2020, Prelude amended its Delaware office and laboratory license to add approximately 8,800 rentable square feet, for approximately 19,800 total. Base fees through December 2022 were expected to total $3.0; a 12-month renewal option would cost $1.4, and a one-time $0.2 payment was made for a right of first offer on additional space.
- Management identified key risks including clinical and regulatory failure or delay, dependence on third-party trial and manufacturing providers (including sole-source suppliers), need for additional capital, competition, intellectual-property protection, and COVID-19 disruption. No material litigation was reported. Management concluded disclosure controls were effective at a reasonable assurance level and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether clinical expansion cohorts enroll on schedule and whether subsequent, sufficiently detailed trial data confirm the early PRT543 and PRT811 observations.
- Whether reported safety findings, patient enrollment, COVID-19 effects, manufacturing supply and regulatory feedback alter the programs’ timelines, costs or prospects.
- Whether cash use remains consistent with management’s runway estimate into the second half of 2022, given rising R&D spending and no revenue or committed financing.
- The potential dilution and voting implications of equity financing, outstanding options and the non-voting common stock conversion provisions; the filing reported 43,703,381 common shares outstanding on November 10, 2020.
- The costs and obligations associated with the expanded laboratory premises and any exercise of the renewal or right-of-first-offer options.